LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1863

Search options

  1. Article ; Online: Another prognostic marker for hepatocellular carcinoma.

    Shao, Yu-Yun

    Hepatology international

    2023  Volume 17, Issue 2, Page(s) 279–280

    MeSH term(s) Humans ; Carcinoma, Hepatocellular/diagnosis ; Carcinoma, Hepatocellular/pathology ; Liver Neoplasms/diagnosis ; Liver Neoplasms/pathology ; Prognosis ; Biomarkers, Tumor
    Chemical Substances Biomarkers, Tumor
    Language English
    Publishing date 2023-03-31
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2270316-0
    ISSN 1936-0541 ; 1936-0533
    ISSN (online) 1936-0541
    ISSN 1936-0533
    DOI 10.1007/s12072-023-10504-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Treatment outcome comparisons of first-line targeted therapy in patients with KRAS wild-type metastatic colorectal cancer: A nationwide database study.

    Liang, Yi-Hsin / Chen, Kuo-Hsing / Shao, Yu-Yun

    Cancer medicine

    2023  Volume 12, Issue 14, Page(s) 15176–15186

    Abstract: Background: The first-line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody ( ... ...

    Abstract Background: The first-line systemic therapy for metastatic colorectal cancer (mCRC) is a combination of one targeted therapy agent and a chemotherapy doublet. Whether bevacizumab or anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (mAb) is the more effective addition to a chemotherapy doublet as the first-line treatment for inoperable KRAS wild-type mCRC remains controversial in prior clinical trials. Moreover, the association between the sidedness of primary tumors and the efficacy of anti-EGFR mAb needs to be addressed.
    Methods: We established a cohort of patients with KRAS wild-type mCRC who were treated with first-line targeted therapy plus doublet chemotherapy between 2013 and 2018 using Taiwan's National Health Insurance Research Database. Secondary surgery was defined as either resection of primary tumors, liver metastases, lung metastases, or radiofrequency ablation.
    Results: A total of 6482 patients were included; bevacizumab and anti-EGFR mAb were the first-line targeted therapies in 3334 (51.4%) and 3148 (48.6%) patients, respectively. Compared with those who received bevacizumab, patients who received anti-EGFR mAb exhibited significantly longer overall survival (OS; median, 23.1 vs. 20.2 months, p = 0.012) and time to treatment failure (TTF; median, 11.3 vs. 10 months, p < 0.001). Among left-sided primary tumors, the OS and TTF benefits of anti-EGFR mAb remained. Among right-sided primary tumors, the OS and TTF were similar regardless of the type of targeted therapy. In multivariate analyses, first-line anti-EGFR mAb therapy remained an independent predictor of longer OS and TTF for left-sided primary tumors. Patients who received anti-EGFR mAb were more likely to receive secondary surgery (29.6% vs. 22.6%, p < 0.0001) than patients who received bevacizumab.
    Conclusion: For patients who received first-line doublet chemotherapy for KRAS wild-type mCRC, adding anti-EGFR mAb was associated with significantly longer OS and TTF, especially for left-sided primary tumors.
    MeSH term(s) Humans ; Bevacizumab/therapeutic use ; Proto-Oncogene Proteins p21(ras)/genetics ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Antibodies, Monoclonal ; Colonic Neoplasms/drug therapy ; Antineoplastic Agents/therapeutic use ; Treatment Outcome ; Rectal Neoplasms/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cetuximab
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2) ; Antibodies, Monoclonal ; Antineoplastic Agents ; Cetuximab (PQX0D8J21J) ; KRAS protein, human
    Language English
    Publishing date 2023-06-16
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2659751-2
    ISSN 2045-7634 ; 2045-7634
    ISSN (online) 2045-7634
    ISSN 2045-7634
    DOI 10.1002/cam4.6196
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Correspondence to: Management of Venous Thromboembolisms: Part II. The Consensus for Pulmonary Embolism and Updates.

    Shao, Yu-Yun / Lin, Hung-Ju

    Acta Cardiologica Sinica

    2020  Volume 37, Issue 2, Page(s) 213–214

    Language English
    Publishing date 2020-02-10
    Publishing country China (Republic : 1949- )
    Document type Journal Article
    ZDB-ID 1051394-2
    ISSN 1011-6842
    ISSN 1011-6842
    DOI 10.6515/ACS.202103_37(2).20210118B
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3059: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma.

    Shao, Yu-Yun / Cheng, Ann-Lii / Hsu, Chih-Hung

    The oncologist

    2021  Volume 26, Issue 5, Page(s) 422–426

    Abstract: Background: Many systemic therapies for advanced hepatocellular carcinoma (HCC) may cause hypothyroidism; however, in these patients, hypothyroidism prevalence before therapy and its prognostic impact remain unclear.: Materials and methods: We ... ...

    Abstract Background: Many systemic therapies for advanced hepatocellular carcinoma (HCC) may cause hypothyroidism; however, in these patients, hypothyroidism prevalence before therapy and its prognostic impact remain unclear.
    Materials and methods: We previously established a prospective cohort of patients who received sorafenib as first-line therapy for advanced HCC. No patients had been clinically diagnosed with hypothyroidism before or during sorafenib treatment. We retrospectively determined the levels of thyrotropin and free thyroxine before initiation of systemic therapy. Hypothyroidism was defined as thyrotropin level higher than the upper limit of the normal range. Among patients with hypothyroidism, free thyroxine level less than the lower normal range was defined as overt hypothyroidism, and free thyroxine level within the normal range was defined as subclinical hypothyroidism.
    Results: In total, 79 patients were enrolled; of them, 16 (20%) had hypothyroidism (overt hypothyroidism, 10; subclinical hypothyroidism, 6). Patients with hypothyroidism, compared with those without hypothyroidism, were more likely to be older than 65 years (56% vs. 29%, p = .037), have a serum α-fetoprotein level of >400 ng/mL (81% vs. 52%, p = .037), and have a significantly poorer overall survival (OS; median, 5.5 vs. 11.6 months, p = .043). After adjusting for other potential prognostic factors, hypothyroidism remained an independent predictor for poorer OS (hazard ratio, 2.53, p = .018). Patients with overt hypothyroidism and subclinical hypothyroidism exhibited similarly poor OS (p = .768).
    Conclusion: Underdiagnosis of hypothyroidism in patients with advanced HCC was common. Hypothyroidism, whether overt or subclinical, is associated with poor prognosis of advanced HCC.
    Implications for practice: The results of this study showed the underdiagnosis of hypothyroidism in patients with advanced hepatocellular carcinoma (HCC) and its influence on prognosis. These findings implied the importance of thyroid function check before initiation of systemic therapy for patients with advanced HCC.
    MeSH term(s) Carcinoma, Hepatocellular/complications ; Humans ; Hypothyroidism/epidemiology ; Liver Neoplasms/complications ; Prospective Studies ; Retrospective Studies
    Language English
    Publishing date 2021-03-20
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1409038-7
    ISSN 1549-490X ; 1083-7159
    ISSN (online) 1549-490X
    ISSN 1083-7159
    DOI 10.1002/onco.13755
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4845: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 494: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study.

    Chen, Ching-Tso / Hsu, Chih-Hung / Cheng, Ann-Lii / Shao, Yu-Yun

    Anticancer research

    2022  Volume 42, Issue 9, Page(s) 4461–4470

    Abstract: Background/aim: The reimbursement criteria of sorafenib for advanced hepatocellular carcinoma (HCC) were expanded in 2016 by Taiwan's National Health Insurance (NHI) to include patients without macrovascular invasion or extrahepatic spread. This study ... ...

    Abstract Background/aim: The reimbursement criteria of sorafenib for advanced hepatocellular carcinoma (HCC) were expanded in 2016 by Taiwan's National Health Insurance (NHI) to include patients without macrovascular invasion or extrahepatic spread. This study explored sorafenib treatment outcomes before and after this expansion.
    Patients and methods: The NHI database was searched for patients who initiated sorafenib treatment between January 1, 2013, and December 31, 2017. Clinical variables were retrieved from the Taiwan Cancer Registry database. Overall survival (OS) and time to treatment discontinuation (TTD) were calculated as the times from the first sorafenib prescription date until death and the final prescription date, respectively.
    Results: A total of 13,862 patients were included. The median age was 64 years, 78.1% of patients were male. Approximately a quarter of patients (25.1%) received sorafenib after the criteria expansion and exhibited significantly longer OS (median 7.9 vs. 6.6 months, p<0.001) and TTD (median 3.0 vs. 2.6 months, p=0.003) compared with patients who started before. These results were verified in patients with available data regarding clinical prognostic factors (n=9,378, 67.7% of the entire study population). In the multivariate analysis, sorafenib prescription after criteria expansion remained an independent predictor of longer OS [hazard ratio (HR)=0.87, p<0.001] and TTD (HR=0.93, p=0.004). In the subgroup analysis, these trends were consistently observed across different patient subgroups.
    Conclusion: Patients with HCC who received sorafenib treatment after the reimbursement criteria expansion exhibited longer OS and TTD.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Carcinoma, Hepatocellular/pathology ; Chemoembolization, Therapeutic/methods ; Female ; Humans ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Niacinamide/therapeutic use ; Phenylurea Compounds/therapeutic use ; Retrospective Studies ; Sorafenib/therapeutic use ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Phenylurea Compounds ; Niacinamide (25X51I8RD4) ; Sorafenib (9ZOQ3TZI87)
    Language English
    Publishing date 2022-08-29
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 604549-2
    ISSN 1791-7530 ; 0250-7005
    ISSN (online) 1791-7530
    ISSN 0250-7005
    DOI 10.21873/anticanres.15946
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1642: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Reply to letter to the editor

    Chih-Horng Wu / Yu-Yun Shao / Tiffany Ting-Fang Shih

    Journal of the Formosan Medical Association, Vol 120, Iss 1, Pp 781-

    Low skeletal muscle mass are predictive factors of survival for advanced hepatocellular carcinoma

    2021  Volume 782

    Keywords Medicine (General) ; R5-920
    Language English
    Publishing date 2021-01-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: It takes two to tango

    Tsung-Hao Liu / Yu-Yun Shao / Chih-Hung Hsu

    Journal of the Formosan Medical Association, Vol 120, Iss 1, Pp 1-

    breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade

    2021  Volume 4

    Keywords Medicine (General) ; R5-920
    Language English
    Publishing date 2021-01-01T00:00:00Z
    Publisher Elsevier
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade.

    Liu, Tsung-Hao / Shao, Yu-Yun / Hsu, Chih-Hung

    Journal of the Formosan Medical Association = Taiwan yi zhi

    2020  Volume 120, Issue 1 Pt 1, Page(s) 1–4

    MeSH term(s) Carcinoma, Hepatocellular/drug therapy ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Liver Neoplasms/drug therapy ; Programmed Cell Death 1 Receptor
    Chemical Substances Immune Checkpoint Inhibitors ; Programmed Cell Death 1 Receptor
    Language English
    Publishing date 2020-07-11
    Publishing country Singapore
    Document type Journal Article
    ZDB-ID 2096659-3
    ISSN 1876-0821 ; 0929-6646
    ISSN (online) 1876-0821
    ISSN 0929-6646
    DOI 10.1016/j.jfma.2020.07.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1041: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan.

    Shao, Yu-Yun / Wang, Shen-Yung / Lin, Shi-Ming

    Journal of the Formosan Medical Association = Taiwan yi zhi

    2020  Volume 120, Issue 4, Page(s) 1051–1060

    Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current ... ...

    Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan had established a management consensus guideline in 2016. The current recommendations focus on updating critical issues regarding the management of HCC, including surveillance, diagnosis, and systemic treatment. For surveillance, the updated guideline suggests the role of dynamic computed tomography or magnetic resonance imaging and contrast-enhanced ultrasound (CEUS) in selected patients. For diagnosis, this update incorporates CEUS and recognizes the role of gadoxetic acid-enhanced magnetic resonance imaging. For systemic therapy, the updated guideline summarizes the multiple choices of targeted therapy, immune checkpoint inhibitors, and the combination of both. Through this update of the management consensus guideline, patients with HCC can benefit from receiving optimal diagnostic and therapeutic modalities.
    MeSH term(s) Carcinoma, Hepatocellular/diagnostic imaging ; Carcinoma, Hepatocellular/therapy ; Contrast Media ; Humans ; Liver Neoplasms/diagnostic imaging ; Liver Neoplasms/therapy ; Magnetic Resonance Imaging ; Taiwan ; Ultrasonography
    Chemical Substances Contrast Media
    Language English
    Publishing date 2020-11-14
    Publishing country Singapore
    Document type Practice Guideline ; Journal Article
    ZDB-ID 2096659-3
    ISSN 1876-0821 ; 0929-6646
    ISSN (online) 1876-0821
    ISSN 0929-6646
    DOI 10.1016/j.jfma.2020.10.031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1041: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer.

    Guo, Jhe-Cyuan / Hsu, Chia-Lang / Hsieh, Min-Shu / Lin, Chia-Chi / Huang, Ta-Chen / Kuo, Hung-Yang / Shao, Yu-Yun / Hsu, Chih-Hung

    Thoracic cancer

    2023  Volume 14, Issue 22, Page(s) 2216–2221

    Abstract: Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to ... ...

    Abstract Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in advanced esophageal squamous cell carcinoma (ESCC). Heterogeneous responses to ICIs have been reported previously. Here, we describe a patient with advanced ESCC exhibiting a response to durvalumab plus tremelimumab for more than 6 months except primary resistant esophageal tumor. The esophageal tumor had higher regulatory T cells, neutrophils, and mast cells scores estimated by NanoString platform than hepatic tumor. The immunohistochemistry study confirmed higher expression levels of Foxp3, and myeloperoxidase (MPO) in the esophageal tumor. The different immune contextures may underlie the heterogeneous responses to ICI combination in this ESCC patient.
    MeSH term(s) Humans ; Esophageal Neoplasms/pathology ; Esophageal Squamous Cell Carcinoma/pathology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunohistochemistry ; Liver Neoplasms
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2023-06-20
    Publishing country Singapore
    Document type Case Reports ; Research Support, Non-U.S. Gov't
    ZDB-ID 2625856-0
    ISSN 1759-7714 ; 1759-7706
    ISSN (online) 1759-7714
    ISSN 1759-7706
    DOI 10.1111/1759-7714.14997
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6921: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top